Alimera Sciences, Inc. (NASDAQ:ALIM) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday.

A number of other equities research analysts have also recently issued reports on ALIM. Cowen and Company set a $3.00 target price on Alimera Sciences and gave the company a “buy” rating in a research note on Thursday, August 3rd. HC Wainwright set a $5.00 target price on Alimera Sciences and gave the company a “buy” rating in a research note on Wednesday, July 26th. Finally, Zacks Investment Research cut Alimera Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $3.38.

Alimera Sciences (ALIM) remained flat at $1.38 during trading on Friday. The company’s stock had a trading volume of 74,441 shares. The stock’s 50 day moving average price is $1.37 and its 200 day moving average price is $1.42. The company’s market cap is $95.29 million. Alimera Sciences has a 52 week low of $1.03 and a 52 week high of $1.72.

Alimera Sciences (NASDAQ:ALIM) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. The company had revenue of $10.40 million during the quarter, compared to the consensus estimate of $10.20 million. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.17) earnings per share. Equities research analysts anticipate that Alimera Sciences will post ($0.21) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Alimera Sciences, Inc. (ALIM) Upgraded to Sell by ValuEngine” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/22/alimera-sciences-inc-alim-upgraded-to-sell-by-valuengine.html.

Several institutional investors and hedge funds have recently modified their holdings of ALIM. Kennedy Capital Management Inc. acquired a new position in shares of Alimera Sciences during the first quarter valued at $467,000. KCG Holdings Inc. increased its holdings in shares of Alimera Sciences by 127.0% during the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 43,977 shares during the period. JW Asset Management LLC increased its holdings in shares of Alimera Sciences by 15.6% during the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after purchasing an additional 130,000 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Alimera Sciences by 24.3% during the second quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock valued at $251,000 after purchasing an additional 35,200 shares during the period. 37.20% of the stock is currently owned by institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.